The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the impact of oral rosuvastatin in diabetic polyneuropathy, and the role of lipid peroxidation and nerve growth factor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alejandra Guillermina Miranda Diaz
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus

• Glycated hemoglobin <12.0%

• Signing of informed consent

• Presence of an abnormality of nerve conduction study

• Symptoms and signs of diabetic polyneuropathy

Exclusion Criteria:

• Pregnancy and lactation

• Foot ulcers

• Treatment with statins

• Antioxidant drug and/or supplements one month previous to enrolment

• Inability to mobilize

• Renal and/or hepatic failure